medRxiv Preprint Server
May 23, 2026
Lisa Maria Jöbstl, Bente Lubahn, Ebru Kaya et al.
preprint
Background While growing enthusiasm for the therapeutic potential of classic psychedelics has led to a rise in non-clinical use, attention to persisting adverse effects has emerged with delay. A subset of individuals reports persisting complications such as hallucinogen persisting perception disorder (HPPD), depersonalization/derealization disorder (DDD), anxiety and depression. Yet few medical...
Journal of Psychoactive Drugs
May 22, 2026
Jamie Walker, Daryle Deering, Bruno Hamish Unger
Opioid dependence is a public health concern in New Zealand, with limited treatment options beyond opioid substitution therapy (OST). Ibogaine, a psychoactive alkaloid with reported anti-withdrawal and anti-craving effects for opioid dependence, is legally available by prescription in New Zealand, offering a context for exploring user experiences. A qualitative collective case study design was...
International Journal of Innovative Science and Research Technology
May 21, 2026
Mengue Assila Marie Serge, N. Mireille
Depersonalization is usually reported as a manifestation in other psychiatric disorders such as psychosis, anxiety, or depression; in physical trauma; or in drug addiction. But it has been very little reported in clinical descriptions relating to bodily injuries such as diabetic foot. This article focuses on the case of four Cameroonian adults with diabetic foot and presenting clinical...
Alcoholism & Drug Abuse Weekly
May 21, 2026
Alison Knopf
New research on the relationship between cannabis and psychosis was released, and a presentation on how low‐dose buprenorphine combined with ketamine reduced suicidality in adults with major depressive disorder was published and presented at the annual meeting of the American Psychiatric Association (APA).
May 21, 2026
Sebastián Malleza
À l'issue de cette activité, les participants devraient être en mesure de : Décrire le mécanisme pharmacologique du dextrométhorphane/bupropion en tant qu'antagoniste oral des récepteurs NMDA et agoniste σ-1 associé à un NDRI inhibiteur du CYP2D6, expliquer comment l'inhibition du CYP2D6 par le bupropion augmente la biodisponibilité du dextrométhorphane et prolonge sa demi-vie d'environ 3 fois,...
May 21, 2026
Sebastián Malleza
Nach Abschluss dieser Fortbildung sollten die Teilnehmer in der Lage sein: Den pharmakologischen Wirkmechanismus von Dextromethorphan/Bupropion als oraler NMDA-Rezeptor-Antagonist und σ-1-Agonist in Kombination mit einem CYP2D6-hemmenden NDRI zu beschreiben, zu erläutern, wie die CYP2D6-Hemmung durch Bupropion die Bioverfügbarkeit von Dextromethorphan erhöht und dessen Halbwertszeit um das ca....
Revista fisio&terapia
May 21, 2026
Flávia Saletti Grecco Dotoli, Isadora Piccolo Estevo
Mindfulness has become one of the most relevant approaches for promoting mental health in contemporary society, being widely applied in clinical, educational, and organizational contexts. It is characterized by the ability to focus attention on the present moment intentionally and without judgment, promoting greater awareness of internal and external experiences. This article aims to analyze...
May 21, 2026
Sebastián Malleza
After completing this activity, participants should be able to: 1. Describe the pharmacological mechanism of dextromethorphan/bupropion as an oral NMDA receptor antagonist and σ-1 agonist paired with a CYP2D6-inhibiting NDRI, explain how bupropion's CYP2D6 inhibition enhances dextromethorphan's bioavailability and extends its half-life ~3-fold, and identify its two FDA-approved indications —...
Translational Psychiatry
May 21, 2026
Francesco Bavato, Andrea E. Steuer, Anna M. Jacobsen et al.
Methamphetamine (METH, "Crystal Meth") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are two types of substituted amphetamines that share structural-chemical similarities but exhibit contrasting acute and chronic effects including addictive liability. Tryptophan (TRY) pathways are involved in pleiotropic physiological functions at the interface of brain-body connections. Preclinical...
May 20, 2026
I. Ivlev, M. Pappas, Tamara P. Cheney et al.
Objective. To evaluate the effectiveness of mindfulness-based interventions (MBIs) and Acceptance and Commitment Therapy (ACT) for mental health and well-being of children and adolescents with and without anxiety, depression, and chronic health conditions. Data sources. Ovid MEDLINE, PsycINFO, Cochrane Library, and ERIC (2009-April 21, 2025); reference lists of relevant reviews. Review methods....